ADAM VTE & Ibrutinib CV Toxicity
from OncoPharm Hosted by John Bossaer
ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 18 minutes long.
When was this OncoPharm episode published?
This episode was published on October 24, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.